Skip to content

Reata Pharmaceuticals Prices Class A Common Stock Offering

Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million.

The offering priced on December 1, 2020 and is expected to close on or about December 4, 2020.

Reata develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

The V&E corporate team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associates Grace-Ann Duquette and Joseph Steuert. Advising on tax matters were partner Wendy Salinas and associate Liz Snyder.

For more information, please speak with our media contacts.